Loading
A phase 3 trial of Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., active and no longer recruiting.
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations is a phase 3 interventional study registered as NCT04687241 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 192 participants planned, started 2021-04-30 and due to reach its primary completion in 2024-07-08. Interventions recorded: Almonertinib, Placebo Almonertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Aumolertinib, Hansoh Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Aumolertinib, Hansoh Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.